MISSED SOMETHING MAJOR in the exclusion criteria
Post# of 148109
(Total Views: 1165)
Posted On: 06/12/2020 6:08:44 PM
MISSED SOMETHING MAJOR in the exclusion criteria
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Did you see this article?
https://emerginggrowth.com/adam-feuersteins-f...empty-net/
Absolutely nailed this point! Darn good analysis - a must read.
Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care.
Did you see this article?
https://emerginggrowth.com/adam-feuersteins-f...empty-net/
Absolutely nailed this point! Darn good analysis - a must read.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼